The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation
- 13 May 2020
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 21 (11), 1367-1376
- https://doi.org/10.1080/14656566.2020.1753698
Abstract
Cardiac allograft vasculopathy (CAV) is a major limitation to long-term survival after heart transplantation. Its peculiar pathophysiology involves multifactorial pathways including immune-mediated and metabolic risk factors, which are associated with the development of specific pathological lesions. The often diffuse and chronic nature of the disease reduces the effectiveness of revascularization procedures, and pharmacological prevention of the disease is the sole therapeutic approach with some proven efficacy. In this article, after briefly outlining the risk factors for CAV, the authors revise the potential pharmacological approaches that may reduce the burden of CAV. While several therapies have shown convincing efficacy in terms of CAV prevention diagnosed by coronary imaging, very few have been reported to improve prognosis with any meaningful level of evidence. The authors believe that a customizable approach is necessary for clinical practice given the currently available evidence. Furthermore, it is important, in the future, to address the glaring therapeutic gap of an effective treatment against donor-specific antibodies, whose effect on endothelial injury is currently one of the major mechanisms of CAV development and for which no pharmacological treatment is currently available.Keywords
This publication has 105 references indexed in Scilit:
- Granulocyte Colony-Stimulating Factor Therapy Is Associated With a Reduced Incidence of Acute Rejection Episodes or Allograft Vasculopathy in Heart Transplant RecipientsTransplantation Proceedings, 2013
- Influence of donor and recipient sex mismatch on heart transplant outcomes: Analysis of the International Society for Heart and Lung Transplantation RegistryThe Journal of Heart and Lung Transplantation, 2012
- Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac TransplantationCirculation, 2012
- Combined Heart and Liver Transplantation: A Single-Center ExperienceTransplantation, 2009
- Mycophenolate Mofetil Reduces Intimal Thickness by Intravascular Ultrasound After Heart Transplant: Reanalysis of the Multicenter TrialAmerican Journal of Transplantation, 2006
- Multi-organ Transplantation: Is There a Protective Effect Against Acute and Chronic Rejection?The Journal of Heart and Lung Transplantation, 2005
- Statins Affect Cell-Surface Expression of Major Histocompatibility Complex Class II Molecules by Disrupting Cholesterol-Containing MicrodomainsHuman Immunology, 2005
- From Clinical Trials to Clinical Practice: An Overview of Certican® (Everolimus) in Heart TransplantationThe Journal of Heart and Lung Transplantation, 2005
- Dependence of diffuse photosynthetically active solar irradiance on total optical depthPublished by American Geophysical Union (AGU) ,2003
- MONITORING OF SOLUBLE HLA ALLOANTIGENS AND ANTI-HLA ANTIBODIES IDENTIFIES HEART ALLOGRAFT RECIPIENTS AT RISK OF TRANSPLANT-ASSOCIATED CORONARY ARTERY DISEASE1Transplantation, 1996